- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT06561958
Prospektivní, multicentrická, neintervenční studie ke zkoumání účinnosti REKOVELLE® pro stimulaci vaječníků u asijských žen v prostředí reálného světa (PROFOUND)
Prospektivní neintervenční studie pro více zemí, která zkoumá REKOVELLE pro stimulaci vaječníků: účinnost, bezpečnost a vzorce použití pro asijské ženy v praxi v reálném světě
Primary objective is to investigate the effectiveness of REKOVELLE® in women undergoing their first REKOVELLE® ovarian stimulation treatment in real world practice in Asian countries.
Přehled studie
Typ studie
Zápis (Aktuální)
Kontakty a umístění
Studijní místa
-
-
-
Hiroshima, Japonsko, 7300035
- Ferring Investigational Site
-
Hokkaido, Japonsko, 0600003
- Ferring Investigational Site
-
Hyōgo, Japonsko, 6500021
- Ferring Investigational Site
-
Osaka, Japonsko, 5300011
- Ferring Investigational Site
-
Osaka, Japonsko, 5500015
- Ferring Investigational Site
-
Saitama, Japonsko, 3540035
- Ferring Investigational Site
-
-
Chiba
-
Chiba, Chiba, Japonsko, 2610023
- Ferring Investigational Site
-
-
Fukuoka
-
Fukuoka, Fukuoka, Japonsko, 8120013
- Ferring Investigational Site
-
Kitakyushu, Fukuoka, Japonsko, 8070825
- Ferring Investigational Site
-
-
Gunma
-
Takasaki, Gunma, Japonsko, 3700841
- Ferring Investigational Site
-
-
Hiroshima
-
Hiroshima, Hiroshima, Japonsko, 7320822
- Ferring Investigational Site
-
-
Japan
-
Bunkyō City, Japan, Japonsko, 1130033
- Ferring Investigational Site
-
-
Tokyo
-
Tokyo, Tokyo, Japonsko, 1600023
- Ferring Investigational Site
-
-
-
-
-
Busan, Jižní Korea, 47245
- Ferring Investigational Site
-
Seoul, Jižní Korea, 02586
- Maria Fertility Hospital
-
-
Busan
-
Busan, Busan, Jižní Korea, 49241
- Ferring Investigational Site
-
-
Daegu
-
Daegu, Daegu, Jižní Korea, 41910
- Ferring Investigational Site
-
-
Seongnam
-
Seongnam-si, Seongnam, Jižní Korea, 13496
- Ferring Investigational Site
-
-
-
-
-
Taichung, Tchaj-wan, 406
- Ferring Investigational Site
-
Taipei, Tchaj-wan, 100225
- Ferring Investigational Site
-
Taipei, Tchaj-wan, 110
- Ferring Investigational Site
-
-
Tainan
-
Tainan, Tainan, Tchaj-wan, 70403
- Ferring Investigational Site
-
Tainan, Tainan, Tchaj-wan, 71004
- Ferring Investigational Site
-
-
Taoyuan
-
Taoyuan, Taoyuan, Tchaj-wan, 333
- Ferring Investigational Site
-
-
-
-
-
Bangkok, Thajsko, 10700
- Ferring Investigational Site
-
-
Muang
-
Phitsanulok, Muang, Thajsko, 65000
- Naresuan University Hospital
-
-
Ratchathewi
-
Bangkok, Ratchathewi, Thajsko, 10400
- Ramathibodi Hospital
-
-
-
-
Hanoi
-
Hanoi, Hanoi, Vietnam, 100000
- Ferring Investigational Site
-
-
Ho Chi Minh City
-
Ho Chi Minh City, Ho Chi Minh City, Vietnam, 700000
- Ferring Investigational Site
-
Ho Chi Minh City, Ho Chi Minh City, Vietnam
- Ferring Investigational Site
-
-
Huế
-
Huế, Huế, Vietnam, 49000
- Ferring Investigational Site
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Approximately 1500 patients prescribed REKOVELLE for the first time for controlled overian stimulation (COS) will be enrolled in the study.
Popis
Inclusion Criteria:
- Females aged 20 years or older at enrollment
- Serum AMH level >0.5 ng / mL (with the latest result tested within 12 months)
- Who are first time prescribed REKOVELLE for their ovarian stimulation and IVF or ICSI treatment cycle using fresh or frozen ejaculated sperm from male partner or sperm donor (if applicable)
- Willing and able to provide written informed consent
Exclusion Criteria:
- Have undergone more than 2 COS-IVF / ICSI cycles before the enrollment
- Participating in an interventional clinical trial in which any medication treatment is mandated
- Women with a contraindication for prescription of REKOVELLE treatment
- Oocyte donors
- Undergoing ovarian stimulation for fertility preservation
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: COHORT
- Časové perspektivy: PROSPECTIVE
Kohorty a intervence
Skupina / kohorta |
Intervence / Léčba |
|---|---|
|
REKOVELLE
Participants prescribed REKOVELLE for the first time for controlled ovarian stimulation. |
Individualised dosing regiment of REKOVELLE in routine clinical practice. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Cumulative live birth rate
Časové okno: Up to 12 months
|
Cumulative live birth rate defined as delivery of at least 1 live fetus after 20 completed weeks of gestation, combined fresh and frozen embryo transfers within 12 months after the start of the ovarian stimulation in patients of the first REKOVELLE ovarian stimulation cycle. |
Up to 12 months
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
The Luteinising hormone (LH) surge suppression protocol
Časové okno: Up to 22 days
|
Treatment pattern will be measured by analysing the Lutenising hormone (LH) surge suppression protocol. |
Up to 22 days
|
|
Daily Dosage
Časové okno: Up to 22 days
|
Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of daily dosage. |
Up to 22 days
|
|
Stimulation Duration
Časové okno: Up to 22 days
|
Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of stimulation duration. |
Up to 22 days
|
|
Total Dosage
Časové okno: Up to 22 days
|
Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of total dosage. |
Up to 22 days
|
|
Trigger Protocol
Časové okno: Up to 22 days
|
Treatment pattern will be measured by analysing the trigger protocol. |
Up to 22 days
|
|
Luteal phase support protocol
Časové okno: Up to 22 days
|
Treatment pattern will be measured by analysing the luteal phase support protocol. |
Up to 22 days
|
|
Number of oocytes retrieved
Časové okno: Up to 22 days
|
Number of oocytes retrieved at oocyte retrieval |
Up to 22 days
|
|
Number of Metaphase II (MII) oocytes
Časové okno: Up to 22 days
|
Number of MII oocytes at oocyte retrieval (only applicable for Intracytoplasmic sperm injection (ICSI)) |
Up to 22 days
|
|
Number of embryos
Časové okno: Day 3 after oocyte retrieval
|
Number of embryos on Day 3 after oocyte retrieved |
Day 3 after oocyte retrieval
|
|
Number of Blastocysts
Časové okno: Day 5 after oocyte retrieval
|
Number of Blastocysts on Day 5 after oocyte retrieved |
Day 5 after oocyte retrieval
|
|
Number of embryos transferred
Časové okno: Up to 28 days
|
Embryos transferred in fresh and/or frozen transfer cycles |
Up to 28 days
|
|
Number of blastocysts transferred
Časové okno: Up to 28 days
|
Blastocysts transferred in fresh and/or frozen transfer cycles |
Up to 28 days
|
|
Implantation rate
Časové okno: Up to 28 days
|
Number of gestational sacs, embryos or blastocysts transferred |
Up to 28 days
|
|
Positive human chorionic gonadotropin (hCG) rate
Časové okno: 11 to 15 days after transfer
|
Positive human chorionic gonadotropin (hCG) rate analysed using serum or urine hCG test 11-15 days after transfer |
11 to 15 days after transfer
|
|
Clinical Pregnancy rate
Časové okno: 4 to 5 weeks after transfer
|
Clinical pregnancy rate (at least 1 gestational sac 4-5 weeks after transfer) |
4 to 5 weeks after transfer
|
|
Vital Pregnancy
Časové okno: 4 to 5 weeks after transfer
|
Vital pregnancy rate (at least 1 intrauterine gestational sac with fetal heartbeat 4-5 weeks after transfer) |
4 to 5 weeks after transfer
|
|
Ongoing pregnancy rate
Časové okno: 9 to 11 weeks after transfer
|
Ongoing pregnancy rate (at least 1 intrauterine viable fetus 9-11 weeks after transfer) |
9 to 11 weeks after transfer
|
|
Time to pregnancy
Časové okno: 4 to 5 weeks after transfer
|
Time to pregnancy from start date of ovarian stimulation to confirmation of clinical pregnancy |
4 to 5 weeks after transfer
|
|
Live birth rate
Časové okno: More than 20 weeks after transfer
|
Live birth is defined as delivery of at least 1 live fetus after 20 completed weeks of gestation within 12 months after the start of the ovarian stimulation in patients of the first REKOVELLE ovarian stimulation cycle. |
More than 20 weeks after transfer
|
|
Multiple pregnancy rate
Časové okno: 4 to 5 weeks after transfer
|
More than 1 gestational sac with fetal heart beat 4-5 weeks after transfer |
4 to 5 weeks after transfer
|
|
Spontaneous abortion rate
Časové okno: Up to 10-11 weeks after transfer
|
Spontaneous abortion is defined as positive hCG test but all intrauterine gestational sacs without fetal heart beat as documented by ultrasound, or there are no viable fetuses observed by ultrasound |
Up to 10-11 weeks after transfer
|
|
Ectopic pregnancy rate
Časové okno: Up to 10-11 weeks after transfer
|
Ectopic pregnancy is defined as extrauterine gestational sac with or without fetal heart beat as documented by ultrasound or surgery. |
Up to 10-11 weeks after transfer
|
|
Estradiol Hormone levels
Časové okno: Up to 20 days
|
Estradiol hormone levels before stimulation and at the end of stimulation day |
Up to 20 days
|
|
Progesterone Hormone levels
Časové okno: Up to 20 days
|
Progesterone hormone levels before stimulation and at the end of stimulation day |
Up to 20 days
|
|
Cycle cancellation rate and the reason for cycle cancellation
Časové okno: Up to 28 days
|
Date when the investigator decides to cancel cycle before oocyte pick up (due to poor ovarian response, excessive ovarian response, any illness which prevents oocyte collection procedure, subject not taking hCG injection at the correct time, subject choice, other) or after oocyte pick-up (due to no oocytes collected, no oocytes fertilized, abnormal fertilization, abnormal embryo development, no embryo development, ovarian hyperstimulation syndrome (OHSS), subject choice, any other specified reason) |
Up to 28 days
|
|
Transfer cancellation rate and the reason for transfer cancellation
Časové okno: Up to 28 days
|
Transfer cancellation rate and the reason for transfer cancellation (no embryo available for transfer, risk of OHSS, endometrium not receptive, high progesterone level, adverse event, any other specified reason for transfer cancellation). |
Up to 28 days
|
|
Frequency and severity of adverse drug reactions (ADRs) and serious adverse events (SAEs)
Časové okno: During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer
|
Frequency and severity of ADRs and SAEs as defined by the investigator |
During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer
|
|
Preventive interventions for ovarian hyperstimulation syndrome (OHSS)
Časové okno: During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer.
|
Preventive interventions decided by the investigator (Triggering of final follicular maturation with GnRH agonist and fresh embryo/blastocyst transfer or cryopreservation, Cancellation of fresh embryo/blastocyst transfer) |
During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer.
|
|
Number of subjects with mild / moderate / severe ovarian hyperstimulation syndrome (OHSS)
Časové okno: During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer
|
Number of subjects with mild / moderate / severe OHSS, defined by the investigator |
During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Ředitel studie: Global Clinical Compliance, Ferring Pharmaceuticals
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 000430
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .